US FDA says lack of evidence for dietary-supplement pathway to CBD regulation

The US Food and Drug Administration (FDA) has rejected a regulatory pathway that would allow CBD products to be treated as food additives or dietary supplements.

The federal agency’s long-awaited pronouncement came today, 26th January, when it said it had denied three citizen petitions it received in the past three years asking it to issue regulations in this sense.

Read full article
I'm already a subscriber

Tiziana Cauli

Senior reporter/health & science editor
Tiziana is an Italian journalist from Sardinia. She has worked for both international and local media in Italy, South Africa, France, Spain, the UK, Lebanon and Belgium. She also worked as a communications manager for several international NGOs in the humanitarian sector.

Our Key Benefits

The global cannabis market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

CannIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

  • Stay informed of any legal and market change in the sector that impacts your organisation
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization